Latest UCB Inc. Stories
ATLANTA, Nov. 18, 2010 /PRNewswire/ -- UCB, Inc., a global leader in the research and development of medications to treat immunology disorders, today announced the winners of its 2010 UCB Rheumatoid Arthritis Family Scholarship Program for outstanding individuals affected by this condition.
ATLANTA, Nov. 9, 2010 /PRNewswire/ -- Today, UCB, Inc. celebrates the academic success of the 2010 UCB Family Epilepsy Scholarship recipients.
ATLANTA, Nov. 2, 2010 /PRNewswire/ -- UCB, a global biopharmaceutical company long recognized for its commitment to the epilepsy community and patient-centered approach, will mark Epilepsy Awareness Month by rolling out new activities and resources at the national and local levels.
ATLANTA, Oct. 14 /PRNewswire/ -- UCB, Inc., a global leader in the research and development of medications to treat immunology disorders, today announced the winners of its 2010 UCB Crohn's and Me Scholarship Program for outstanding individuals affected by this condition.
BRUSSELS, July 28 /PRNewswire/ -- UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that NeuproÂ® (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of Restless Legs Syndrome (RLS).
BRUSSELS, June 17 /PRNewswire-FirstCall/ -- New data presented this week at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina (June 13-17, 2010) showed that NeuproÂ® (rotigotine transdermal system) provided significantly greater improvement in early morning motor symptoms and sleep quality, compared with placebo, and as measured by the Unified Parkinson's Disease Rating Scale and the Parkinson's Disease Sleep Scale. The latest data come...
ATLANTA, June 14 /PRNewswire/ -- Lt.
ATLANTA, June 14 /PRNewswire/ -- UCB today announced the availability of an oral solution formulation of VimpatÂ® (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of partial-onset seizures in people with epilepsy age 17 years and older.